Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ LILRA2 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5113285
Description
LILRA2 Polyclonal Antibody for Western Blot, IHC (P), ELISA
Leukocyte Ig-like receptors (LIRs) are a family of immunoreceptors expressed predominantly on monocytes and B cells and at lower levels on dendritic cells and natural killer (NK) cells. All LIRs in subfamily B have an inhibitory function (LILRB1; MIM 604811). LIRs in subfamily A, with short cytoplasmic domains lacking an immunoreceptor tyrosine-based inhibitory motif (ITIM) and with trans membrane regions containing a charged arginine residue, may initiate stimulatory cascades. One member of subfamily A (LILRA3; MIM 604818) lacks a transmembrane region and is presumed to be a soluble receptor.
Specifications
| LILRA2 | |
| Polyclonal | |
| Unconjugated | |
| LILRA2 | |
| CD85 antigen-like family member H; CD85h; ILT1; ILT-1; Immunoglobulin-like transcript 1; leucocyte Ig-like receptor A2; leukocyte immunoglobulin like receptor A2; leukocyte immunoglobulin-like receptor 7; Leukocyte immunoglobulin-like receptor subfamily A member 2; leukocyte immunoglobulin-like receptor subfamily A member 2 soluble; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA2; LIR7; LIR-7 | |
| Rabbit | |
| Protein G | |
| RUO | |
| 11027 | |
| -20°C or -80°C if preferred | |
| Liquid |
| ELISA, Immunohistochemistry (Paraffin), Western Blot | |
| 2 mg/mL | |
| PBS with 50% glycerol and 0.03% ProClin 300; pH 7.4 | |
| Q8N149 | |
| LILRA2 | |
| Recombinant Human Leukocyte immunoglobulin-like receptor subfamily A member 2 protein (9-275AA). | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction